European Heart Journal-Cardiovascular Pharmacotherapy

Papers
(The TQCC of European Heart Journal-Cardiovascular Pharmacotherapy is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure47
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-1947
Prevention is still the key to success40
Sex-based differences in risk of ischaemic stroke or systemic embolism after BNT162b2 or CoronaVac COVID-19 vaccination in patients with atrial fibrillation: a self-controlled case series and nested c39
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis35
Anticoagulation in cancer-associated thrombosis: how long should the therapy be?34
Response: Letter to the editor30
Oral anticoagulants and antiplatelet treatment in different settings29
GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity29
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries29
ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE228
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation28
Antithrombotic therapy following revascularization for chronic limb-threatening ischaemia: a European survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases26
Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials25
Balancing the risks of bleeding and ischaemia in myocardial infarction patients at high bleeding risk23
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials23
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate22
Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis22
More knowledge about atrial fibrillation, still we need to learn22
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics21
Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction21
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure21
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome19
What's new in pharmacotherapy at ESC Congress 2023?18
Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors17
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease16
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials16
What is optimal dual anti-platelet therapy duration after percutaneous coronary intervention?16
Response—letter to the editor: colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns15
Updated ACC/AHA/HFSA 2022 guidelines on heart failure: what is new? From epidemiology to clinical management15
Cardiovascular risks associated with use of non-steroidal anti-inflammatory drugs in patients with non-obstructive coronary artery disease15
Comment on Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization15
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study15
Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism in patients with inflammatory joint disease—results from the nationwide Norwegian Cardio-rheuma registry14
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials14
Adherence to pharmacological treatment: how can we improve?14
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 202214
Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials14
Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events14
Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients13
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study13
Fibrates: one more lost paradise in lipid treatment13
Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis13
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance12
Associations between medical therapy after surgical aortic valve replacement for aortic stenosis and long-term mortality: a report from the SWEDEHEART registry12
Atrial fibrillation has gone from a boring disease to a very hot condition. Why is that?12
Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk12
Thromboprophylaxis for COVID-19-related coagulopathy: what next?12
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on12
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients12
Reduction of hypokalaemia with finerenone: a drug or class-specific effect?12
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial12
LDL lowering effect of PCSK9 inhibition is reduced in women12
Targeting Lipoprotein(a): Pharmacotherapy in Focus12
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study12
Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases11
Subcutaneous furosemide in heart failure: a systematic review11
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials11
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?10
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study10
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlle10
Proton pump inhibitors: seeking the golden ratio between gastroprotection and cardiovascular risk10
High- vs. low-dose diclofenac and cardiovascular risks: a target trial emulation10
Estimated impact of guidelines-based initiation of dual antihypertensive therapy on long-term cardiovascular outcomes in 1.1 million individuals10
Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 20219
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consens9
Sodium–glucose co-transporter 2 inhibitors in heart failure9
Re: Shahim et al., 2024 “Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction”9
Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial9
Unsolved pharmacological issues with cardiology9
After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension9
Corrigendum to: “2019 guidelines for the diagnosis and management of chronic coronary syndromes”: congratulations and tribulations9
Cost-effectiveness of Implementing a Genotype-Guided De-Escalation Strategy in Patients with Acute Coronary Syndrome8
New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics8
Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi after myocardial infarction: reply8
Pharmacogenetic testing to broaden patient eligibility for mavacamten8
What is new in the 2023 AHA/ACC multisociety guideline on chronic coronary disease?8
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient8
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis8
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia8
The search for the perfect antiplatelet treatment continues7
PharmaPulse: new trial evidence from the HFA/ESC Heart Failure Congress 20217
Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns7
Renal protection in chronic heart failure: focus on sacubitril/valsartan7
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective7
Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry7
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials7
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study7
New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 20217
Outcomes after delayed primary percutaneous coronary intervention vs. pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway7
Pre-treatment with dual antiplatelet therapy in non-ST-segment elevation acute coronary syndromes: landing from guidelines recommendations to real-world ground7
0.063302993774414